Viatris (VTRS) stock
Health Care · Pharmaceuticals
Viatris (VTRS) is a Pharmaceuticals company in the Health Care sector, headquartered in Pittsburgh, Pennsylvania. As of October 23, 2026, VTRS closed at $18.00, a market capitalization of $20.67 billion, the 401st largest company in the S&P 500. Over the last twelve months it generated $14.74 billion in revenue (+5% year over year) and $1.81 billion in free cash flow.
- 1-year total return: +80.8% (dividends reinvested)
- 5-year return: +9.8% a year
- 52-week range: $9.92 – $18.75
- Gross margin 40.3%, operating margin 12.6%
- Dividend yield: 2.67%
- FI Handbook report card: C- across 10 metrics
- 48th largest of 60 Health Care stocks in the S&P 500
VTRS price chart
1Y price change: +74.6% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| VTRS | +5.1% | +48.0% | +80.8% | +31.8% | +9.8% | -4.8% | +6.4% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1980.
VTRS key statistics
- Market cap
- $20.7B
- #401 in S&P 500
- P/E (TTM)
- —
- Forward P/E
- 6.7x
- EPS (TTM)
- $-0.36
- Revenue (TTM)
- $14.7B
- +5%
- Free cash flow
- $1.8B
- Gross margin
- 40.3%
- Operating margin
- 12.6%
- Return on equity
- -2.8%
- Dividend yield
- 2.67%
- 52-week range
- $9.92 – $18.75
- Beta
- 0.86
- Price / sales
- 1.4x
- EV / EBITDA
- 7.6x
- Debt / equity
- 0.96x
- Employees
- 30,000
VTRS report card
C-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth4.9%D
- Gross margin40.3%B
- Operating margin12.6%C
- FCF margin12.3%C
- Return on equity-2.8%F
- Net debt / EBITDA2.8xD
- Forward P/E6.7xA
- PEG ratio3.3xF
- Shareholder yield5.1%A
- Share count change / yr18.5%F
Viatris financials
Revenue went from $11.3B in fiscal 2018 to $14.3B in fiscal 2025, growing 3.4% a year.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.3B | $11.4B | $11.8B | $17.8B | $16.2B | $15.4B | $14.7B | $14.3B |
| Gross profit | $4.0B | $3.9B | $3.8B | $5.6B | $6.5B | $6.4B | $5.6B | $5.0B |
| Operating income | $905.6M | $715.5M | -$210.8M | -$34.0M | $1.6B | $766.2M | $10.1M | -$2.7B |
| Net income | $352.5M | $16.8M | -$669.9M | -$1.3B | $2.1B | $54.7M | -$634.2M | -$3.5B |
| EPS (diluted) | $0.68 | $0.03 | $-1.11 | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |
| Free cash flow | $2.1B | $1.6B | $988.8M | $2.6B | $2.6B | $2.5B | $2.0B | $1.9B |
| Buybacks | $432.0M | $0 | $0 | $0 | $0 | $250.0M | $250.0M | $500.5M |
| Diluted shares | 516.5M | 516.5M | 601.2M | 1.2B | 1.2B | 1.2B | — | — |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into VTRS?
A reverse DCF asks what growth the current price requires. With an enterprise value of $32.8B and $1.8B of trailing free cash flow, Viatris needs to grow free cash flow about 8.1% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 14.4% a year over the last five years.
P/E ratio history
Current 184.6x vs. median 198.3x (10th–90th percentile 5.7x–549.9x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
VTRS dividend
- Dividend yield
- 2.67%
- Annual dividend
- $0.48
- Years of increases
- —
- 5-yr dividend growth
- 32.0%
- per year
- Payout ratio
- 960%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
VTRS analyst price targets
10 analysts' average 12-month target is $19.90 (+11% vs. $18.00). Targets range from $13.00 to $26.00. 58% rate it a buy.
VTRS earnings
Next report: November 5, 2026. Viatris has beaten EPS estimates 6 quarters in a row. Last quarter's revenue was $3.8B (+5% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 6, 2026 | $0.60 | $0.69 | +15.0% |
| May 7, 2026 | $0.50 | $0.59 | +17.5% |
| Feb 26, 2026 | $0.53 | $0.57 | +7.4% |
| Nov 6, 2025 | $0.62 | $0.67 | +8.5% |
| Aug 7, 2025 | $0.56 | $0.62 | +11.6% |
| May 8, 2025 | $0.49 | $0.50 | +1.6% |
| Feb 27, 2025 | $0.57 | $0.54 | -5.6% |
| Nov 7, 2024 | $0.68 | $0.75 | +10.7% |
Stocks like VTRS
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 MRK Merck & | -1.34% | +72% | $358.4B | 117.2x | Compare |
 PFE Pfizer | -1.28% | +30% | $171.2B | 39.5x | Compare |
 BMY Bristol-Myers Squibb | -2.41% | +47% | $125.6B | 13.5x | Compare |
 ZTS Zoetis | -1.18% | -44% | $33.5B | 13.3x | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
VTRS news
- Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal Framing · Oct 23, 2026
- A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack · Oct 21, 2026
- Viatris’ Dividend Has Room to Grow, but Will Management Deliver? · Oct 19, 2026
- Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia · Oct 16, 2026
- Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus · Oct 12, 2026
VTRS stock FAQ
What is VTRS's market cap?
Viatris's market capitalization is $20.67 billion as of October 23, 2026, ranking 401st in the S&P 500.
Does VTRS pay a dividend?
Yes. Viatris pays $0.48 per share a year, a 2.67% yield. Dividends grew 32.0% a year over the last five years.
How much has VTRS stock returned?
Including reinvested dividends, VTRS returned +80.8% over one year, +9.8% a year over five years, -4.8% a year over ten years through October 23, 2026.
Is VTRS stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Viatris must grow free cash flow about 8% a year for the next decade. Its free cash flow grew 14% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the VTRS price target?
10 analysts cover VTRS with an average 12-month price target of $19.90, +11% from the current price. 58% of them rate it a buy.
When does VTRS report earnings?
Viatris is expected to report earnings on November 5, 2026. It has beaten EPS estimates 6 quarters in a row.
How many employees does Viatris have?
Viatris has about 30,000 full-time employees, or $491,243 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology